Enhanced Pharmaceutical Composition and Process for Canagliflozin
Legal Citation
Summary of the Inventive Concept
A novel pharmaceutical composition and process for Canagliflozin, providing improved stability, bioavailability, and manufacturing efficiency, overcoming limitations of existing compositions.
Background and Problem Solved
The original patent disclosed a pharmaceutical composition comprising Canagliflozin, but it had limitations such as instability, low bioavailability, and time-consuming manufacturing processes. The new inventive concept addresses these limitations by introducing novel excipients, solvents, and manufacturing processes, enhancing the overall performance of the composition.
Detailed Description of the Inventive Concept
The new inventive concept comprises a pharmaceutical composition of Canagliflozin with a novel binder-free excipient, granulated using a unique solvent system, and formulated with a novel combination of lubricants to enhance tablet compression. Additionally, the composition can be coated with a novel enteric coating to delay release in the gastrointestinal tract. The manufacturing process is optimized with a novel granulation process that reduces processing time by at least 30%. Furthermore, the composition can be administered with a novel solubility enhancer to increase absorption, improving bioavailability.
Novelty and Inventive Step
The new claims introduce novel and non-obvious improvements over the original patent, including the use of binder-free excipients, unique solvent systems, and novel lubricant combinations. These innovations provide significant advantages in terms of stability, bioavailability, and manufacturing efficiency.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include varying the ratio of Canagliflozin to excipients, using different solvents or granulation processes, or incorporating additional ingredients to enhance performance. Variations of the composition could be designed for specific patient populations or therapeutic indications.
Potential Commercial Applications and Market
The enhanced pharmaceutical composition and process for Canagliflozin have significant commercial potential in the treatment of type 2 diabetes and other metabolic disorders. The improved stability, bioavailability, and manufacturing efficiency of the composition make it an attractive option for pharmaceutical companies and healthcare providers, with a potential market size in the billions of dollars.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical formulation and drug delivery, specifically focused on sodium-dependent glucose transporter inhibitor compositions, requiring expertise in pharmaceutical chemistry, excipient selection, and drug formulation techniques
Person of Ordinary Skill (PHOSITA) Profile
A pharmaceutical formulation scientist with advanced degree (MS/PhD) in pharmaceutical sciences, 3-5 years experience in drug development, familiar with excipient interactions, granulation techniques, and tablet manufacturing processes
Obviousness Rationale
A PHOSITA would recognize that the PTD's variations represent predictable engineering solutions to known pharmaceutical formulation challenges, utilizing standard pharmaceutical techniques to incrementally improve the original Canagliflozin composition. The modifications involve routine optimization strategies commonly employed in pharmaceutical development, such as adjusting excipient ratios, exploring alternative granulation methods, and enhancing bioavailability through standard pharmaceutical approaches.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,559 |
|---|---|
| Title | Pharmaceutical composition comprising Canagliflozin, process of preparation and use thereof |
| Assignee(s) | Aurobindo Pharma Ltd |